Life sciences industry’s search for talent is becoming more challenging: study
While more professionals are engaged in life sciences research in the U.S. and a record number of people are graduating in the biological and biomedical sciences, the ability of employers to find life sciences research talent is proving extremely difficult, according to a new report from CBRE. Read More
Patient advocacy organizations look to partner with pharma companies
Patient advocacy organizations are looking to partner with pharmaceutical companies, offering resources and expertise to maximize the impact and efficiency of their therapeutic R&D programs. It’s a message that these groups want to drive home to pharma at the 2022 Biotechnology Innovation Organization International Convention in San Diego. Read More
How to develop a sustainable portfolio for cell, gene therapy platforms
Michael Retterath, a Biotechnology Innovation Organization International Convention 2022 panelist and chief business officer at Spark Therapeutics, spoke to ScienceBoard.net about his company’s transition from a research center to a private, venture-backed startup and a publicly traded company. Read More
Biotech industry execs, not scientists, remain male-dominated
A panel at the 2022 Biotechnology Innovation Organization International Convention will explore how to close the gender gap in the biotech industry and how it can become more inclusive. ScienceBoard.net spoke with Nasha Fitter, co-founder and CEO of the FOXG1 Research Foundation, who will participate in the June 14 panel at the convention. Read More
The ‘voice of the patient’ needs to be heard in clinical trials: study
Patient recruitment and retention are among the biggest challenges facing clinical research, particularly in studies targeting rare diseases that have a limited pool of patients, contends Clincierge CEO Scott Gray. He spoke with ScienceBoard.net about Clincierge's study examining the patient experience in clinical trials of rare diseases. Read More
Taking cell therapy to the next level with 3D bioprinting of human tissues
Aspect Biosystems is working to create breakthrough tissue therapeutics that have the potential to profoundly impact patients with 3D bioprinting of human tissues, contends Eric Roos, chief business development officer. Roos spoke with ScienceBoard.net at the American Society of Gene & Cell Therapy 2022 annual meeting in Washington, DC. Read More
Overcoming the blood-brain barrier for gene therapy delivery with AAV capsids
Current gene delivery to the central nervous system continues to be a challenge, according to Amy Pooler, PhD, vice president of neuroscience at Sangamo Therapeutics. Pooler spoke with ScienceBoard.net at the American Society of Gene & Cell Therapy 2022 annual meeting about how Sangamo’s adeno-associated virus (AAV) capsids are designed to overcome the blood-brain barrier. Read More
From China to Princeton: Yibin Kang's journey as an immigrant scientist to disrupt cancer metastasis
It's been an amazing odyssey of scientific discovery for Yibin Kang, PhD, Warner-Lambert/Parke-Davis professor of molecular biology at Princeton University. Born in a small fishing village in China, Kang from an early age had a strong interest in nature and science -- a passion that led to his becoming a cancer biologist in the U.S. Read More
Decibel Therapeutics develops treatments to restore and improve hearing, balance
Decibel Therapeutics is helping to break down the barriers to understanding the molecular pathways and cell physiology inside the inner ear by integrating single-cell genomics, bioinformatic analyses, and precision gene therapy technologies, contends CEO Laurence Reid, PhD. Reid spoke with ScienceBoard.net at the American Society of Gene & Cell Therapy 2022 annual meeting in Washington, DC. Read More
Mustang Bio focuses on CD20 antigen for CAR T-cell therapy
Biopharmaceutical company Mustang Bio is focused on a CD20-targeted autologous chimeric antigen receptor (CAR) T-cell therapy for non-Hodgkin lymphoma, chronic lymphocytic leukemia, and Waldenstrom macroglobulinemia. Dr. Bruce Dezube, senior vice president at Mustang Bio, spoke to ScienceBoard.net at the American Society of Gene & Cell Therapy 2022 annual meeting about the targeting of the CD20 antigen. Read More
Conferences
Science Briefs
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Connect
